It has been previously reported that transient corticosteroid immune suppression of ponies experimentally infected with a highly neutralization resistant envelope variant of equine infectious anemia virus (EIAV), designated EIAV DPND , resulted in the appearance of type-specific serum antibodies to the infecting EIAV DPND virus. The current study was designed to determine if this induction of serum neutralizing antibodies was associated with changes in the specificity of envelope determinants targeted by serum antibodies or caused by changes in the nature of the antibodies targeted to previously defined surface envelope gp90 V3 and V4 neutralization determinants. To address this question, the envelope determinants of neutralization by post-immune suppression serum were mapped. The results demonstrated that the neutralization sensitivity to post-immune suppression serum antibodies mapped specifically to the surface envelope gp90 V3 and V4 domains, individually or in combination. Thus, these data indicate that the development of serum neutralizing antibodies to the resistant EIAV DPND was due to an enhancement of host antibody responses caused by transient immune suppression and the associated increase in virus replication.
INTRODUCTION

Equine infectious anemia virus (EIAV) is a lentivirus that causes a persistent infection and dynamic disease in equids.
The dynamic nature of EIAV infection is in marked contrast to the slowly progressive degenerative diseases usually associated with the other members of the lentivirus family, such as HIV and SIV (Montelaro et al., 1993) . Experimental EIAV infection in horses results in a characteristic disease progression. Within one month of infection, horses typically experience acute viraemia and disease characterized by fever, thrombocytopenia, diarrhoea, lethargy, oedema and other clinical signs. Following resolution of acute disease, infected horses typically progress to chronic disease characterized by recurring disease cycles at irregular intervals separated by weeks or months (Montelaro et al., 1993) . The recurring disease cycles have been associated with the evolution of antigenic variants of the virus that are able to temporarily escape established immune surveillance, such that distinct populations of EIAV envelope quasispecies are present at each disease cycle (Leroux et al., 1997; Lichtenstein et al., 1996; Payne et al., 1987) . By 8-12 months post-infection most horses become long-term asymptomatic carriers indefinitely, unless stressed or immune suppressed to cause a recrudescence of disease. The progression from chronic disease to inapparent carrier has been associated with a complex and lengthy development of enduring and broadly controlling host immunity that is able to suppress virus replication to subclinical levels, despite ongoing envelope antigenic variation (Craigo et al., 2002; Hammond et al., 2000; Harrold et al., 2000; Leroux et al., 2001; Montelaro et al., 1993) . It is the unique ability of the equine immune system to maintain EIAV replication and disease under strict lifelong control that makes the EIAV system a useful model for the natural immune control of lentivirus infection and disease.
EIAV replication and disease is directly related to host immune response, and not to attenuation of the infecting virus (Issel et al., 1982; Perryman et al., 1988) . For example, dexamethasone-induced immune suppression of inapparent carriers results in the recrudescence of disease associated with markedly increased virus replication (Craigo et al., 2002; Kono et al., 1976; Mealey et al., 2001; Tumas et al., 1994) . The evolution of humoral and cellular immune responses during the progression from chronic disease to inapparent carrier status has been examined and characterized in detail (Hammond et al., 1997; McGuire et al., 2002; Mealey et al., 2003; Rwambo et al., 1990a; Tschetter et al., 1997; Zhang et al., 1998) . The results of these studies have indicated that an 8-10 month time period post-infection is required for the development of a mature steady-state immunity that can mediate effective and enduring control of EIAV replication and disease. Interestingly, a similar length of time post-infection with attenuated EIAV is required for the development of maximum immune protection from virus exposure (Hammond et al., 1999; Li et al., 2003; Montelaro et al., 1996 Montelaro et al., , 1998 .
The role of specific humoral and cellular immune responses in mediating enduring protective immunity remains to be defined, but a combination of these immune factors is likely to function in a synergistic manner. In this regard, there is contradictory data on the potential role of neutralizing antibody responses in protective immunity. Virusspecific neutralizing antibody is typically not detected in experimentally infected equids until about 3 months postinfection, apparently precluding a role for neutralizing antibody in resolving acute viraemia and disease. However, neutralizing antibodies steadily increase in titre and breadth of neutralization specificity during the first year postinfection. Steady-state levels are reached concomitant with the achievement of sustained immune control of EIAV replication and disease observed in long-term inapparent carriers (Hammond et al., 1997; Howe et al., 2002; Rwambo et al., 1990a) . Finally, the envelope variation observed during sequential disease episodes results in alterations in serum neutralization sensitivity, suggesting escape from critical antibody control (Howe et al., 2002; Leroux et al., 1997; Montelaro et al., 1984; Payne et al., 1987; Rwambo et al., 1990b) . These observations indicate a dynamic interaction between evolving virus populations and host immune responses in which neutralizing antibodies can be a determinant of control or escape.
Antigenic variation during persistent EIAV infection has been correlated with alterations in the surface (SU) gp90 and transmembrane (TM) gp45 envelope proteins, including amino acid substitutions and deletions, and frequent alterations in potential N-linked glycosylation sites (Hussain et al., 1987; Leroux et al., 2001; Payne et al., 1987; Rwambo et al., 1990b; Zheng et al., 1997) . While variation may occur throughout the envelope sequence, variation is predominantly localized to the gp90 protein. Studies of EIAV envelope variation have identified eight conserved and eight variable regions within the heavy glycosylated gp90. In addition, a principal neutralizing domain (PND), located in the hypervariable V3 segment of the SU, has been suggested based on the presence of two adjacent neutralizing epitopes, E nt and D nt . Another neutralizing epitope, C nt , has been identified in the V5 region of gp90 (Ball et al., 1992; Grund et al., 1996; Hussain et al., 1987 Hussain et al., , 1988 Leroux et al., 1997 Leroux et al., , 2001 ). We recently reported on detailed neutralization epitope mapping studies using reciprocal domain substitutions between neutralization sensitive and resistant EIAV envelopes (Howe et al., 2002) . The results of these studies indicated the V3 and V4 domains as the predominant determinants of gp90 sensitivity or resistance to neutralization by immune serum from experimentally infected equids.
The present investigation expands on a previous study of the in vivo neutralization characteristics of an experimental infection-derived, in vitro neutralization-resistant virus isolate, EIAV PV564DPND (Craigo et al., 2002; Leroux et al., 1997) . To determine the effect of this PND deletion on envelope immunogenic properties and host immune control, two ponies were experimentally infected with an EIAV proviral construct containing the DPND envelope, EIAV DPND (Craigo et al., 2002) . Both experimentally infected ponies remained asymptomatic for EIA and experienced relatively low levels of plasma viral RNA during the 14-month observation period. In addition, both ponies produced high steady-state levels of EIAV envelope-specific antibodies, but developed only minimal neutralizing antibodies to the infecting EIAV DPND . Our initial interpretation of these data was that the PND domain gp90 was required for the production of neutralizing antibodies during persistent infection, indicating that the deletion in V3 affected envelope immunogenicity as well as antigenicity. To assess the role of host immune responses in control of virus replication, both ponies were transiently immune suppressed with a 10-day dexamethasone treatment that culminated with both animals developing EIA associated with a 4-log increase in virus loads. In characterizing the virus-specific host immunity in response to the dexamethasone treatment, we unexpectedly observed that high-titre, strain-specific, neutralizing antibodies against EIAV DPND developed postimmune suppression concomitant with a 100-fold reduction in steady-state plasma virus loads in the absence of significant gp90 amino acid variation. Post-immune suppression serum did not neutralize the parental EIAV PV , indicating highly type-specific serum neutralization. While differing markedly in antibody neutralization phenotypes, EIAV DPND and EIAV PV envelope amino acid sequences differ by only 1?8 %, including a 14 aa deletion in the V3 domain and a shift in an N-linked glycosylation site in the V4 domain the EIAV DPND gp90. Thus, these studies demonstrate that transient immune suppression and increased viraemia resulted in a modification of steadystate host immunity to the infecting virus and production of neutralizing antibody responses to a neutralization 'resistant' DPND envelope. This current study was designed to elucidate the mechanism behind the marked change in host immunity by differentiating between two possible routes to altering serum antibody neutralization properties. First, the transient immune suppression and increased viraemia may have induced antibodies to new envelope epitopes outside the previously defined V3 and V4 neutralization domains. Alternatively, the development of serum neutralization to the EIAV DPND could be attributed to quantitative or qualitative changes in antibody responses to the defined V3 and V4 neutralization domains. In the current study, we have used the unique combination of EIAV DPND and EIAV PV envelopes that differ in neutralization sensitivity to post-immune suppression serum to distinguish between these alternative mechanisms of immune modulation.
METHODS
Experimental infections, clinical evaluations, and virus and serum isolations. Two outbred ponies (animals #599 and #672) were intravenously inoculated with 1610 3 TCID 50 EIAV DPND as described previously in Craigo et al. (2002) . The clinical progression, virus evolution, plasma virus load and host immune responses of these experimentally infected ponies have been described previously (Craigo et al., 2002) and are summarized in Fig. 1 . Selected immune serum samples taken from the experimentally infected ponies at regular intervals pre-and post-immune suppression were used in this study to define the neutralization phenotypes of the EIAV envelope variants.
Construction of chimeric envelopes between neutralization sensitive and resistant EIAV envelope variants. Based on the observed in vitro neutralization phenotypes defined by post-immune suppression serum with our reference EIAV PV and the variant envelope EIAV DPND (Craigo et al., 2002) , these gp90 envelope proteins were chosen as reference neutralization resistant and sensitive envelopes, respectively. To elucidate the gp90 neutralization determinants, reciprocal chimeric envelopes exchanging defined variable domains were constructed and tested for their neutralization properties against the panel of reference immune serum from both ponies #599 and #672 on day 443 (post-immune suppression). To generate the desired mutations in the V3 and/or V4, and C6 regions, internal primers containing overlapping sequence mutations were used with external primers flanking the BlpI and BstXI restriction enzyme sites. The PCR was performed by using the Expand High Fidelity PCR system (Roche), 0?025 mM each deoxynucleoside triphosphate, 0?1 mM of each primer and 1?5 ml of original template or purified PCR fragments in a final volume of 100 ml. The following conditions were used: 4 min at 95 uC, after which 0?4 ml of Expand High Fidelity enzyme was added; 1 min at 95 uC, 1?5 min at 50 uC and 1 min at 72 uC for 35 cycles; 10 min at 72 uC for one cycle. The resulting 1?6 kb env fragments were digested with BlpI and BstXI prior to ligation with T4 ligase (NEB) into the vector containing the EIAV UK genome (GenBank accession no. AF016316) with the corresponding 1?6 kb fragment removed. The ligation products were used to transform competent E. coli DH5a cells (Invitrogen). Clones from each of the new chimera constructs were screened by BamHI restriction enzyme digests for the presence of the insert and sequenced as described previously (Leroux et al., 1997) to confirm the correct envelope sequence. The in vitro replication properties of each of the variable region chimeras were then assessed by individually transfecting a 4 mg sample of purified plasmid DNA from each of the resulting env variant proviral clones into 10 5 fetal equine kidney (FEK) cells following the manufacturer's directions for the GenePorter Transfection kit (GTS). Virus production was monitored every 5 days by measurements of the reverse transcriptase activity in the supernatants of the transfected cells using a standard micro-RT assay (Leroux et al., 1997) . The TCID 50 values of supernatants from transfected FEK cell cultures were then determined in a standardized infectious centre assay in FEK cells that uses a cell-based ELISA detection system (Hammond et al., 1997) .
Serum antibody neutralization assays. The level of neutralization activity of the panel of reference immune serum from the experimentally infected ponies against the variant and chimeric envelope proviruses was determined using a standard viral infectious centre assay, as described previously (Hammond et al., 1997) . Briefly, 10 5 FEK cells were added into a 24-well tissue culture plate and allowed to adhere overnight at 37 uC. All immune serum samples were heat inactivated before use in the assay. Twofold serial dilutions of each of the serum samples were incubated in the presence of 100 infectious units of the selected chimeric virus at 37 uC for 1 h. The serum-virus mixture was then added to the cells and incubated overnight at 37 uC. An overlay of 0?8 % carboxmethylcellulose was added to the infected cultures and incubated for a further 7 days at 37 uC. The cells were then fixed and permeabilized. Reference immune serum from an EIAV-infected horse (Lady) was used as a primary antibody, followed by an affinity-purified, horseradish peroxidase-conjugated, goat anti-horse immunoglobulin G (Sigma). The peroxidase substrate 3-amino-9-ethyl-carbazole (Sigma) in a sodium acetate buffer (pH 5?5) supplemented with H 2 O 2 , was used to visualize the EIAV infectious centres. The number of infectious centres was counted, and the 50 % reciprocal neutralization titre of each serum sample was determined by linear regression analysis. Titres below 1 : 20 are considered background as determined with uninfected control sera. Each neutralization assay was repeated at least twice to determine standard error values. Neutralization titres were compared using paired t-test analyses to determine statistical significance.
RESULTS
Clinical and serological profiles pre-and post-immune suppression
The sources of virus and immune serum used in these studies were two mixed-breed ponies (#599 and #672) intravenously infected with the previously described replication competent, neutralization resistant EIAV DPND , as reported in detail by Craigo et al. (2002) . Over an observation period of 410 days, both EIAV DPND -infected animals remained asymptomatic for EIA, reflecting relatively low steady-state levels of plasma RNA (Fig. 1a, c) . Beginning on day 420 post-infection, both ponies were transiently immune suppressed for 10 days with dexamethasone producing a febrile episode with corresponding drop in platelets and associated increase in viraemia (Fig. 1a, c) . Clinical signs were resolved by day 434 postinfection, and plasma viral RNA copies declined to steadystate levels 100-fold lower than those observed before immune suppression (Fig. 1a, c) .
Prior to immune suppression, both animals had developed a high EIAV envelope-specific antibody end-point titre averaging 1610 6 , which increased to a titre of 1610 7 postimmune suppression (Fig. 1b, d) . EIAV DPND -envelopespecific 50 % neutralizing antibody titres were around 1 : 50 in both animals prior to immune suppression. However, after immune suppression and resulting fever, envelope-specific neutralizing antibodies were detected against the infecting EIAV DPND strain with titres of 1 : 275 in pony #599 and 1 : 550 in pony #672. Sequence analysis pre-and post-immune suppression revealed 3-4 % variation within the gp90 consistent with previously observed evolution rates and the retention of the V3 deletion. Interestingly, at no time before or after dexamethasone treatment did either animal develop serum antibodies capable of neutralizing the parental EIAV PV strain (Fig. 1b, d ).
This lack of envelope-specific neutralizing antibody against EIAV PV and abundant neutralizing antibody against EIAV DPND was unexpected due to the low level of gp90 variation observed between these two viruses (Fig. 2) . The few areas of sequence variation between the two viral envelopes were localized to the V3, V4 and C6 regions of the envelope gp90. The V3 region contained the most extensive variation between the two viral envelopes including the 14 aa deletion of the PND E nt epitope in the EIAV DPND . Other minor variations observed in the EIAV DPND compared to the EIAV PV envelope involved the shifting and addition of potential N-linked glycosylation sites in the V4 and C6 domains, respectively. These variations in EIAV DPND from its parent EIAV PV were retained after immune suppression and resolution of disease (Craigo et al., 2002) . Thus, these studies provided a novel panel of envelope variants and immune serum to examine the basis for the development of neutralizing antibodies to the EIAV DPND envelope after transient immune suppression of the inapparent carriers.
EIAV gp90 V3 and V4 as determinants of neutralization sensitivity
Previous studies with EIAV variant envelopes differing in neutralization phenotypes indicate that the V3 and V4 regions of the envelope can confer neutralization specificity either individually or in concert with each other (Howe et al., 2002) . Thus, considering that two of the sites of variation between EIAV DPND and EIAV PV were within the V3 and V4 domains, we first sought to examine if the serum neutralizing antibodies induced by transient immune suppression were specific for the V3 or V4 domains of gp90. Towards this objective, a panel of chimeric viruses was constructed containing variable region exchanges of either the V3 domain, V4 domain or a combination of the V3 and V4 domains between the neutralization resistant EIAV PV envelope backbone (gp90 PV ) or in the neutralization sensitive EIAV DPND envelope backbone (gp90 DPND ) (Fig. 3a) . Characterization of the replication properties of the panel of chimeric envelope proviruses with substituted variable domains (Fig. 3b) demonstrated that all of the constructs containing substitutions of the EIAV DPND envelope V3 and V4 domains, singly or in combination, into the resistant EIAV PV backbone displayed replication properties similar to the parental viruses. In contrast, the reverse chimeric viruses containing the individual EIAV PV envelope V3 or V4 domains substituted into the EIAV DPND backbone were replication defective, whereas the double V3V4 chimera was replication competent. These results support previous findings indicating the requirement for a functional compatibility between the envelope V3 and V4 regions to support virus replication (Chen et al., 2001; Howe et al., 2002) . Thus, the replication competent chimeric envelope proviruses were used to assess the sensitivity of the respective V3 and V4 domains as targets for serum neutralizing antibodies produced by transient immune suppression.
The neutralization phenotypes of the variable region exchange chimeras and the two parental envelope variants were examined with serum obtained from the two experimentally infected ponies after immune suppression and resolution of disease and suppression of viraemia (day 443). Using our standard in vitro neutralization assay, the reciprocal 50 % neutralization titre of the immune serum to each envelope construct was determined (Fig. 4) . Immune serum samples from both experimentally infected ponies displayed a similar pattern of virus neutralization activity against the respective variable region chimeric viruses, indicating a common effect of immune suppression on host antibody responses. As a reference, immune serum samples taken after transient immune suppression (day 443) of the two ponies were shown to have mean neutralization titres of about 1 : 20 against the parental resistant EIAV PV envelope provirus (gp90 PV ) (Fig. 4) . In contrast, the same post-immune suppression serum samples displayed substantial neutralization activity levels against the EIAV DPND envelope provirus (gp90 DPND ) with a mean neutralization titre of about 1 : 400 (Fig. 4) .
Substitution of the V3 domain from the neutralization sensitive EIAV DPND envelope into the EIAV PV backbone [gp90 PV (V3)] resulted in an increase in serum neutralization sensitivity against the post-immune serum to a mean of 1 : 850, compared with 1 : 10 neutralization observed with the parental EIAV PV envelope (gp90 PV ). The introduction of the EIAV DPND V4 domain into the neutralization resistant EIAV PV backbone [gp90 PV (V4)] also induced an increase in neutralization sensitivity post-immune suppression to a mean titre of 1 : 225, compared with the 1 : 10 neutralization titre observed for the neutralization resistant parental envelope gp90 PV. Interestingly, the serum neutralization titres measured against gp90 PV (V3) with the postimmune suppression serum samples were on mean twofold higher than the neutralization titre observed with parental neutralization sensitive envelope gp90 DPND . These data indicate that the V3 and V4 domains independently serve as predominant targets of the serum neutralizing antibodies induced by transient immune suppression.
The most dramatic increase in neutralization sensitivity occurred when both the V3 and V4 variable regions of the neutralization sensitive EIAV DPND were substituted into the neutralization resistant EIAV PV backbone [gp90 PV (V3V4)] (Fig. 4) . Immune serum from both ponies demonstrated a marked increase in their serum neutralizing antibody titres against the gp90 PV (V3V4) to a mean of 1 : 8600, compared with the 1 : 10 neutralization titre observed with the parental envelope gp90 PV , post-immune suppression. These data indicated a highly additive effect of the V3 and V4 domain substitutions in conferring serum neutralization sensitivity to the parental neutralization resistant EIAV PV .
As a complement to the preceding analyses, we next evaluated the neutralization sensitivity of the replication competent reciprocal chimeric envelope virus in which the V3 and V4 domains of the neutralization resistant EIAV PV envelope were substituted into the neutralization sensitive EIAV DPND envelope backbone (Fig. 3a, b) . Neutralization analysis of this gp90 DPND (V3V4) proviral construct demonstrated a 10-fold reduction in serum neutralization sensitivity compared with the parental gp90 DPND envelope provirus. Thus, the 50 % neutralizing antibody titres for the post-immune suppression serum from the two ponies was calculated to be a mean titre of 1 : 20 against the gp90 DPND (V3V4) envelope provirus, compared with a mean titre of about 1 : 400 against the parental envelope gp90 DPND (Fig. 4 ). These data demonstrate that the gp90 V3 and V4 domains are the predominant determinants of neutralization resistance to the post-immune suppression serum.
Taken together, the preceding combination of experiments evaluating changes in neutralization sensitivity and resistance, respectively, indicate that the V3 and V4 domains are the predominant determinants of neutralization sensitivity in post-immune suppression serum. These results suggest that the development of serum neutralizing antibodies by transient immune suppression was associated with changes in the qualitative or quantitative host antibody responses to the gp90 V3 and V4 domain and not to changes in the envelope determinants targeted by serum antibodies.
Evaluation of C6 glycosylation variation on neutralization sensitivity
The V4 region encompasses 7 aa that encode a single potential N-linked glycosylation site that is shifted only by two residues in the neutralization sensitive envelope gp90 DPND compared with the gp90 PV (Fig. 2) . Since we observed a significant change in neutralization sensitivity based on this defined glycosylation variation, we next evaluated the effect of other variations in potential Nlinked glycosylation sites within the gp90 on neutralization specificity. One of the few envelope variations observed outside the V3 and V4 regions was the introduction of a glycosylation site in the conserved C6 region of the EIAV DPND envelope that is not present in the C6 domain of the EIAV PV envelope (Fig. 2) . To address the effect of the additional glycosylation site within the C6 domain on serum neutralization phenotype, a panel of conserved C6 domain exchange chimeras was constructed (Fig. 5a) . The C6 region of the neutralization sensitive EIAV DPND was substituted into the parental neutralization resistant EIAV PV backbone [gp90 PV (C6)] and into the highly neutralization sensitive gp90 PV (V3V4) provirus construct [gp90 PV (V3V4C6)]. Reciprocal C6 exchanges from the neutralization resistant EIAV PV were also substituted into the neutralization sensitive EIAV DPND backbone [gp90 DPND -(C6)] and into the engineered resistant gp90 DPND (V3V4) construct [gp90 DPND (V3V4C6)]. All of the new C6 exchange chimeras were replication competent (Fig. 5b) . In general, each of the chimeras had similar replication kinetics and similar RT levels by 30 days post-transfection.
The neutralization properties of the two parental envelope variants and each of the C6 chimeric envelope viruses were determined using the reference post-immune suppression serum samples from both ponies, as described above. Using our standard in vitro neutralization assay, the reciprocal 50 % neutralization titre of each envelope construct was determined (Fig. 6) . The data demonstrated that substitution of the neutralization sensitive EIAV DPND C6 domain into the EIAV PV backbone did not increase the sensitivity of the latter envelope to neutralization by the postimmune suppression serum (Fig. 6a) . Similarly, substitution of the C6, V3 and V4 domains from the neutralization sensitive EIAV DPND into the resistant EIAV PV backbone, [gp90 PV (V3V4C6)], failed to increase the neutralization sensitivity over the levels seen with V3V4 substitution alone (Fig. 6a ). These observations indicate that the C6 is not a major determinant of envelope neutralization sensitivity to post-immune suppression serum antibodies. Fig. 4 , were individually transfected into FEK cells in duplicate. Supernatants from each transfected culture were collected at regular intervals over a 30-day period. The levels of RT present in the samples at each time point were measured in a micro-RT assay as described in Methods. Fig. 6 . Serum neutralization properties of the C6 region chimeric envelope proviral constructs. Post-immune suppression serum samples were selected from each pony to test the effect of exchanging specific variable regions on in vitro neutralization phenotypes as described in Methods. The 50 % neutralizing antibody titres were determined for day 443 (15 days postimmune suppression) (solid bars) post-infection for each of the replication competent variable region exchange chimeric viruses. Each experiment was run in duplicate and repeated twice. Asterisk (*) indicates the neutralizing antibody titres that are significantly different (P¡0?05) from the parental backbone at that specific time point. (a) Pony #599, (b) pony #672.
The exchange of the non-glycosylated C6 region from the neutralization resistant EIAV PV into the neutralization sensitive EIAV DPND backbone [gp90 DPND (C6)] demonstrated less consistent results between animals then previously seen with the V3 and V4 region exchanges (Fig. 6b) . The serum neutralization titres observed with pony #599 immune serum against gp90 DPND (C6) increased from 1 : 275 to 1 : 4000 post-immune suppression (Fig. 6a) , indicating an unexpected increase in serum neutralization sensitivity. In contrast, the serum neutralization titres of pony #672 against gp90 DPND (C6) appeared to decrease slightly to 1 : 440 compared with the titre of 1 : 525 observed with the parental gp90 DPND (Fig. 6b) . However, substitution of the same gp90 DPND C6 into the engineered gp90 DPND (V3V4) chimera failed to alter the neutralization properties of either pony serum relative to the parental gp90 DPND provirus; serum neutralization titres for both proviral envelopes were approximately 1 : 15 (Fig. 6a, b) . Thus, the data presented in Fig. 6(a) , excluding the pony #599 serum reactivity to gp90 DPND (C6) envelope, are consistent with the idea that the variant glycosylation in C6 domain is not a major determinant of envelope neutralization properties in this situation. The reason for the unexpected but unique serum neutralization reactivity of the serum from pony #599 to the C6 domain is unclear. However, this variation may reflect the outbred nature of these ponies and the intrinsic differences in host immunity.
DISCUSSION
The primary goal of this study was to determine the mechanisms leading to the production of highly typespecific neutralizing antibodies by transient immune suppression of ponies experimentally infected with a previously defined neutralization resistant EIAV DPND strain. Two alternative models were considered for the induction of neutralizing antibodies by the transient immune suppression. The first model proposed that the transient immune suppression resulted in qualitative or quantitative changes in host antibody responses to previously defined predominant neutralization determinants in the V3 and V4 domains of the viral envelope. The second model proposed that the transient immune suppression resulted in a redirection of host antibody responses to new envelope determinants outside the principal neutralizing domain. The results presented here clearly indicate that the gp90 V3 and V4 domains are the predominant determinants for neutralization sensitivity by post-immune suppression serum. Thus, these observations support the concept that transient immune suppression and the associated wave of viraemia and antigenic stimulation can modify quantitative and qualitative properties of host antibody responses leading to an enhancement of serum neutralizing antibodies. In this regard, it is interesting to note that the transient immune suppression of these experimentally infected ponies resulted in a substantial reduction in steady-state virus replication levels as immune responses recovered from the dexamethasone treatment (cf. Fig. 1 ), perhaps in part due to the development of serum neutralizing antibodies.
Montefiori and colleagues have reported a similar enhancement of serum neutralizing antibodies to HIV-1 in patients subjected to structured interrupted antiviral drug therapy regimens (Montefiori et al., 2001; Ortiz et al., 1999 Ortiz et al., , 2001 , suggesting a general role for transient waves of virus replication in boosting host immune control of persistent virus infection. However, the basis for the increase in serum neutralization to HIV-1 was undefined. While most lentivirus infections are associated with progressively degenerative diseases, the episodic nature and eventual immune control of EIAV replication and disease are unique among lentiviruses. Based on the observations presented here it is interesting to speculate that the enduring natural immunologic control of virus replication and disease achieved in horses infected with EIAV may in part be due to the discrete waves of viraemia characteristic of this persistent infection and their ability to boost host immunity.
The exact mechanisms by which transient waves of viraemia, naturally or experimentally induced, can markedly modify the specificity of host antibody responses to lentivirus infections remains to be elucidated. However, this immune modulation appears to be related to a 'boosting' effect of the increased virus antigen presentation during the viraemia that cannot be accomplished by a steady-state virus-immune system status. Based on this model, one can postulate that the transient immune suppression and subsequent viraemia modify the existing viral envelopespecific antibody responses by boosting memory immune responses to critical viral envelope determinants. In the case of EIAV, the development of neutralizing antibody responses after transient immune suppression clearly correlates with changes in antibody targeted to the V3 and V4 domains of the gp90 envelope protein. It cannot be concluded from the current data whether this alteration is due only to quantitative increases in antibody levels to these principal neutralizing domains or also to qualitative changes in antibody population. Envelope-specific antibody titres increased only slightly in response to the dexamethasone treatment, while neutralizing antibody titres to the infecting EIAV DPND increased from background levels (<1 : 20) to a mean of about 1 : 400. Thus, these data are consistent with the concept of substantial qualitative changes in envelope-specific antibodies in the absence of significant changes in the quantitative levels of envelopespecific antibodies.
The studies described here also elucidate further the antigenic architecture of the EIAV envelope glycoprotein and define in more detail envelope antibody neutralization determinants and the effects of natural variation on neutralization sensitivity. We previously identified the EIAV gp90 V3 domain as a principal neutralizing domain using synthetic peptide mapping of neutralizing monoclonal antibodies (Ball et al., 1992) . These studies defined two adjacent neutralizing monoclonal antibody binding sites (D nt and E nt ) in the V3 domain loop of gp90 (Fig. 2) . Subsequent comparisons of natural variant EIAV envelopes differing in serum neutralization sensitivity confirmed the role of the V3 domain and identified the relatively small V4 domain as a second predominant neutralizing domain (Howe et al., 2002) . Despite the small number of animals presented here, the current studies reconfirm the role of the gp90 V3 and V4 domains as principal neutralization determinants of the EIAV envelope and their ability individually or in combination to confer neutralization sensitivity when substituted into a resistant envelope (e.g. EIAV PV ). From the analyses of the EIAV DPND envelope neutralization determinants, it was demonstrated that the D nt epitope of the V3 domain, in the absence of the adjacent E nt epitope, can serve as an effective target for serum neutralization. The characterization of the EIAV DPND envelope also highlighted the role of the potential N-linked glycosylation site in the 7-residue V4 domain in determining neutralization sensitivity, with absolute resistance or sensitivity being dictated by a shift in the glycosylation site by only 2 aa. While the V4 glycosylation site location was shown to be a major determinant of EIAV neutralization properties, the current data indicated that the differences in the number of N-linked glycosylation sites in the gp90 C6 domain in general did not affect envelope neutralization sensitivity. While all variations in envelope glycosylation may not be related to antigenic variation, the role of lentivirus envelope glycosylation variation in defining envelope antigenic and immunogenic properties is becoming increasingly evident (Back et al., 1994; Cheng-Mayer et al., 1999; Johnson & Desrosiers, 2002; Lue et al., 2002; Ly & Stamatatos, 2000; Malenbaum et al., 2000; Polzer et al., 2002; Quinones-Kochs et al., 2002) . Our current working model to explain the interaction of the V3 and V4 domains as neutralization determinants is that the V3 domain is the actual target for neutralizing antibodies and that the V4 glycosylation site affects the accessibility of these V3 sequences to antibody neutralization.
Taken together, this series of studies indicates that the V3 and V4 domains are predominant targets for neutralizing antibody responses, but that the ability of the immune system to respond to these targets is apparently influenced by the overall context of antigen presentation, particularly the V3-V4 domain interactions. For example, neutralizing antibodies are routinely produced in equids experimentally infected with EIAV PV , but these neutralizing antibodies fail to inactivate the EIAV DPND envelope (Howe et al., 2002; Leroux et al., 1997) . Conversely, the neutralizing antibodies elicited by transient immune suppression of ponies experimentally infected with EIAV DPND failed to inactivate the EIAV PV envelope (Craigo et al., 2002) . These observations suggest that the initial exposure of the EIAV envelope to the host immune system may restrict the specificity of neutralizing antibody responses to the highly variable envelope domains, similar to the original antigenic sin described for other virus and bacterial infections (Fazekas & Webster, 1966; Good et al., 1993; Klenerman & Zinkernagel, 1998; Mongkolsapaya et al., 2003; Tsuchiya et al., 2000) . Studies in HIV have suggested that the initial antibody response to the immunodominant epitopes of the hypervariable V3 region may impede the future responses to emerging variants, thus provided the virus with a window of opportunity to escape immune surveillance (Kohler et al., 1994; Locher et al., 1999) . Overcoming original antigenic sin for vaccine development is not a new problem and several other viral vaccines, such as dengue haemorrhagic fever, influenza, malaria and Lymphocytic choriomeningitis virus have been impeded by this immune restriction (Fazekas & Webster, 1966; Good et al., 1993; Klenerman & Zinkernagel, 1998; Mongkolsapaya et al., 2003; Tsuchiya et al., 2000) and continue to be an ongoing question for HIV vaccines (Kundu et al., 1998; Nara & Garrity, 1998; Singh et al., 2002; Verschoor et al., 1999) .
